DK0610336T3 - Behandling af neurologiske tilstande ved hjælp af en interleukin-1-hæmmende forbindelse - Google Patents

Behandling af neurologiske tilstande ved hjælp af en interleukin-1-hæmmende forbindelse

Info

Publication number
DK0610336T3
DK0610336T3 DK92922537T DK92922537T DK0610336T3 DK 0610336 T3 DK0610336 T3 DK 0610336T3 DK 92922537 T DK92922537 T DK 92922537T DK 92922537 T DK92922537 T DK 92922537T DK 0610336 T3 DK0610336 T3 DK 0610336T3
Authority
DK
Denmark
Prior art keywords
interleukin
treatment
pct
inhibitory compound
neurological conditions
Prior art date
Application number
DK92922537T
Other languages
English (en)
Inventor
Gareth Roberts
Nancy Jane Rothwell
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919123161A external-priority patent/GB9123161D0/en
Priority claimed from GB919125670A external-priority patent/GB9125670D0/en
Application filed by Univ Manchester filed Critical Univ Manchester
Application granted granted Critical
Publication of DK0610336T3 publication Critical patent/DK0610336T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK92922537T 1991-10-31 1992-11-02 Behandling af neurologiske tilstande ved hjælp af en interleukin-1-hæmmende forbindelse DK0610336T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919123161A GB9123161D0 (en) 1991-10-31 1991-10-31 Treatment of neurological conditions
GB919125670A GB9125670D0 (en) 1991-11-30 1991-11-30 Treatment of neurogical conditions
PCT/GB1992/002023 WO1993008820A1 (en) 1991-10-31 1992-11-02 Treatment of neurological conditions by an interleukin-1 inhibiting compound

Publications (1)

Publication Number Publication Date
DK0610336T3 true DK0610336T3 (da) 2002-07-22

Family

ID=26299779

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92922537T DK0610336T3 (da) 1991-10-31 1992-11-02 Behandling af neurologiske tilstande ved hjælp af en interleukin-1-hæmmende forbindelse

Country Status (10)

Country Link
US (1) US6090775A (da)
EP (1) EP0610336B1 (da)
JP (1) JP3623501B2 (da)
AT (1) ATE214939T1 (da)
AU (3) AU2884592A (da)
CA (1) CA2122596C (da)
DE (1) DE69232516T2 (da)
DK (1) DK0610336T3 (da)
ES (1) ES2173871T3 (da)
WO (2) WO1993008819A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
ATE270550T1 (de) * 1995-04-07 2004-07-15 Teijin Ltd Wirkstoff zum schutz für organ oder gewebe
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US20030040660A1 (en) * 2001-08-27 2003-02-27 George Jackowski Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
WO2003022213A2 (en) * 2001-09-06 2003-03-20 Board Of Regents, The University Of Texas System Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
EP1863847A2 (en) * 2004-12-02 2007-12-12 Domantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
BRPI0619224A2 (pt) * 2005-12-01 2017-06-20 Domantis Ltd monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
AU2010203425B2 (en) * 2009-01-09 2015-04-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of corneal disorders
EP2598526B1 (en) 2010-07-29 2018-09-05 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
DK2968468T3 (en) 2013-03-13 2021-07-26 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
IL100535A (en) * 1986-12-31 1994-05-30 Hoechst Roussel Pharma Pharmaceutical preparations containing a history of xanthine to relieve disease states
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
AU5921890A (en) * 1989-06-13 1991-01-08 Smithkline Beecham Corporation Monokine activity interference
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases

Also Published As

Publication number Publication date
US6090775A (en) 2000-07-18
AU7648296A (en) 1997-02-13
JPH07505608A (ja) 1995-06-22
WO1993008820A1 (en) 1993-05-13
EP0610336B1 (en) 2002-03-27
JP3623501B2 (ja) 2005-02-23
DE69232516D1 (de) 2002-05-02
ES2173871T3 (es) 2002-11-01
ATE214939T1 (de) 2002-04-15
WO1993008819A1 (en) 1993-05-13
AU2804192A (en) 1993-06-07
CA2122596C (en) 2008-06-03
CA2122596A1 (en) 1993-05-13
EP0610336A1 (en) 1994-08-17
DE69232516T2 (de) 2002-10-31
AU2884592A (en) 1993-06-07

Similar Documents

Publication Publication Date Title
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
DK0610336T3 (da) Behandling af neurologiske tilstande ved hjælp af en interleukin-1-hæmmende forbindelse
SE9604793D0 (sv) New polymorphs
DE69904576D1 (de) Zur behandlung von cmv infektionen geeignete 1,3,4-thiadiazole
DK1334731T3 (da) Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel
DK0897726T3 (da) Antipruritisk middel
NO20012977L (no) N-ureidoalkylpiperidiner som modulatorer av chemokinreseptoraktivitet
DK0641328T3 (da) Broforbundne, azabicykliske derivater som substans P-antagonister
ATE184594T1 (de) Sulfonamidderivate als aspartylprotease- inhibitoren
ES2108120T3 (es) Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
DE59400489D1 (de) Fungizide Wirkstoffkombinationen
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
DK0772603T3 (da) Substituerede pyrimidinforbindelser og deres anvendelse
BR9606547A (pt) Novos derivados de pirimidona com atividade fungicida
BR0113590A (pt) 7-oxo-piridopirimidinas
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
AU7713891A (en) Use of substituted 1,2,4-triazinediones
ATE332145T1 (de) Arzneien zur begleitenden behandlung von glaukomen
KR910004191A (ko) 신질환치료제
DK0935461T3 (da) Adamantanaminderivater til bekæmpelse af virus fra Borna viridae familien
TR199701497T1 (xx) Beyin �demini �nleyen terkip.
ITMI920955A1 (it) Idrogeli di tipo polietereammidoamminico come materiali eparinizzabili
HU0201394D0 (da)
MX9304075A (es) Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.
FI953002A (fi) Menetelmä kroonisen eturauhastulehduksen hoitamiseksi 17beta-N-monosubstituoiduilla karbamoyyli-4-atsa-5alfa-androst-1-en-3-oneilla